Page 18 - Read Online

Atmaja et al. J Cancer Metastasis Treat 2021;7:xx https://dx.doi.org/10.20517/2394-4722.2021.66 Page 13 of 14

38. Choueiri TK, Plimack E, Arkenau HT, et al. Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell
cancer. J Clin Oncol 2017;35:2993-3001. DOI PubMed
39. Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal
cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol 2017;35:591-7. DOI PubMed PMC
40. Choueiri TK, Escudier B, Powles T, et al. METEOR Investigators. Cabozantinib versus everolimus in advanced renal-cell carcinoma.
N Engl J Med 2015;373:1814-23. DOI PubMed PMC
41. Gad S, Lefevre SH, Khoo SK, et al. Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic
chromophobe renal cell carcinoma. Br J Cancer 2007;96:336-40. DOI PubMed PMC
42. Higgins JP, Shinghal R, Gill H, et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray.
Am J Pathol 2003;162:925-32. DOI PubMed PMC
43. Yamazaki K, Sakamoto M, Ohta T, et al. Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 2003;22:847-52.
DOI PubMed
44. Haitel A, Susani M, Wick N, et al. c-kit overexpression in chromophobe renal cell carcinoma is not associated with c-kit mutation of
exons 9 and 11. Am J Surg Pathol 2005;29:842. DOI PubMed
45. Polascik TJ, Cairns P, Epstein JI, et al. Distal nephron renal tumors: microsatellite allelotype. Cancer Res 1996;56:1892-15. PubMed
46. Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 2017;376:354-66. DOI PubMed
47. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N
Engl J Med 2012;366:883-92. DOI PubMed PMC
48. Pal SK, Sonpavde G, Agarwal N, et al. Evolution of circulating tumor DNA profile from first-line to subsequent therapy in metastatic
renal cell carcinoma. Eur Urol 2017;72:557-64. DOI PubMed
49. Park I, Lee JL, Ahn JH, et al. Active surveillance for metastatic or recurrent renal cell carcinoma. J Cancer Res Clin Oncol
2014;140:1421-8. DOI PubMed
50. Rini BI, Dorff TB, Elson P, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol
2016;17:1317-24. DOI PubMed
51. Heng DYC, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma:
results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2014;66:704-10. DOI PubMed
52. Bex A, Mulders P, Jewett MAS, et al. Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous
metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME). Ann Oncol 2017;28:V622. DOI
53. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after Nephrectomy in metastatic renal-cell carcinoma. N Engl J Med
2018;379:417-27. DOI PubMed
54. Méjean A, Thezenas S, Chevreau C, et al. Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena
trial with focus on intermediate IMDC-risk population. J Clin Oncol 2019;37:4508-8. DOI
55. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients
with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90. DOI PubMed PMC
56. Pal SK, Nelson RA, Vogelzang N. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted
therapy era. PLoS One 2013;8:e63341. DOI PubMed PMC
57. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumanb plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a
randomized, double-blind phase III trial. Lancet 2007;370(9605):2103-11. DOI PubMed
58. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018;359:1350-5. DOI PubMed PMC
59. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Eng J Med
2010:363711-23. DOI PubMed PMC
60. Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer
(CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883-95. DOI PubMed
61. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med
2019;380:1103-15. DOI PubMed
62. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med
2019;380:1103-15. DOI PubMed PMC
63. Choueiri TK, Powles T, Burotto M, et al; CheckMate 9ER Investigators. Nivolumab plus Cabozantinib versus Sunitinib for advanced
renal-cell carcinoma. N Engl J Med 2021;384:829-41. DOI PubMed
64. Motzer RJ, Escudier B, Gannon A, et al. Sunitinib: ten years of successful clinical use and study in advanced renal cell carcinoma.
Oncologist 2017;22:41-52. DOI PubMed PMC
65. Gee MS, Procopio WN, Makonnen S, et al. Tumor vessel development and maturation impose limits on the effectiveness of anti-
vascular therapy. Am J Pathol 2003;162:183-93. DOI PubMed PMC
66. Kotecha RR, Motzer RJ, Voss MH. Towards individualized therapy for metastatic renal cell carcinoma. Nature 2019;16:621-33. DOI
PubMed
67. Gao W, Li W, Xiao T, Liu XS, Kaelin WG Jr. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-
/- clear cell renal carcinoma. Proc Natl Acad Sci U S A 2017;114:1027-32. DOI PubMed PMC
68. Motzer R, Alekseev B, Rha SY, et al; CLEAR Trial Investigators. Lenvatinib plus Pembrolizumab or Everolimus for advanced renal
cell carcinoma. N Engl J Med 2021;384:1289-300. DOI PubMed
69. Grunwald V, Powles T, Choueiri TK, et al. Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell
carcinoma: study design and rationale. Future Oncol 2019;15:929-41. DOI PubMed